Key terms
About PSTX
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PSTX news
Mar 25
4:06pm ET
Poseida Therapeutics names Syed Rizvi, M.D., as Chief Medical Officer
Mar 13
4:07pm ET
Poseida Therapeutics granted FDA orphan designation for P-BCMA-ALLO1
Mar 12
6:58pm ET
Poseida Therapeutics’ treatment of multiple myeloma gets FDA orphan designation
Mar 11
2:32am ET
3 Best Stocks to Buy Now, 3/11/2024, According to Top Analysts
Mar 08
7:50am ET
Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)
Mar 08
6:28am ET
Buy Rating for Poseida Therapeutics Amid Strong Financials and Promising Clinical Updates
Mar 08
5:25am ET
William Blair Sticks to Its Buy Rating for Poseida Therapeutics (PSTX)
Mar 07
4:26pm ET
Poseida Therapeutics Announces Executive Leadership Change
Mar 07
4:12pm ET
Poseida Therapeutics reports Q4 EPS (27c), consensus (39c)
Jan 07
5:40am ET
BTIG Keeps Their Buy Rating on Poseida Therapeutics (PSTX)
Jan 04
10:20am ET
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX) and Rhythm Pharmaceuticals (RYTM)
Jan 02
9:48am ET
BTIG Reaffirms Their Buy Rating on Poseida Therapeutics (PSTX)
Dec 31
5:24am ET
Poseida Therapeutics (PSTX) Gets a Buy from BTIG
No recent news articles are available for PSTX
No recent press releases are available for PSTX
PSTX Financials
Key terms
Ad Feedback
PSTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PSTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range